Sophie Kim supports Clinical Operations, helping drive clinical trial execution. Sophie joined Imbria from Dragonfly Therapeutics, where she led day-to-day operations and supported oversight of two early-phase oncology studies.
Prior to Dragonfly, Sophie held research and discovery roles at Vesigen Therapeutics, Visterra Inc., and Dana-Farber Cancer Institute. She holds a BS in Biology from Boston College.
Imbria and third parties use cookies and similar technologies for site functions and analytics. We use optional cookies only if you accept. You can manage your choices at any time.
Manage your cookie preferences below:
Essential cookies enable basic functions and are necessary for the proper function of the website.
Google reCAPTCHA helps protect websites from spam and abuse by verifying user interactions through challenges.
Statistics cookies collect information anonymously. This information helps us understand how visitors use our website.
Google Analytics is a powerful tool that tracks and analyzes website traffic for informed marketing decisions.
Service URL: policies.google.com
You can find more information in our Privacy Policy.